TRIUMPH-1: The 28.3% Retatrutide Result
The result is the reason everyone is searching. The medicine still is not approved in Australia, so the first page has to separate trial data from what buyers can actually check today.
Direct answer
Lilly reported that the 12 mg retatrutide arm in TRIUMPH-1 lost an average of 70.3 lb, or 28.3%, at 80 weeks. The 9 mg arm lost 25.9% and the 4 mg arm lost 19.0%. Retatrutide is still investigational and is not an approved Australian medicine today.
Research peptides are not approved by the TGA for human use. Supplier links are for checking visible batch and payment details, not medical advice.
4 mg arm
19.0% at 80 weeks
47.2 lb average reduction
9 mg arm
25.9% at 80 weeks
64.4 lb average reduction
12 mg arm
28.3% at 80 weeks
70.3 lb average reduction
12 mg arm, >=30% loss
45.3% of participants
Lilly's reported TRIUMPH-1 topline result
Top dose, BMI under 30
65.3% of participants
Reported in Lilly's May 2026 release
Source: Eli Lilly and Company TRIUMPH-1 topline release, published 21 May 2026. This page summarises the reported topline data and does not provide medical advice.
Reviewed for
TRIUMPH-1 topline numbers
Australian approval status
No dosing or medical advice
Published 23 May 2026. Medical reviewer pending. No clinician credential is claimed.
The short answer
Direct answer
The headline result is 28.3% average body-weight reduction at 80 weeks in Lilly's reported 12 mg arm.
Lilly reported 28.3% average body-weight reduction in the 12 mg arm after 80 weeks. In plain language, that was a 70.3 lb average reduction in the reported trial population.
That is why the retatrutide search spike is real. The data is public, but the medicine is still not a finished Australian pharmacy product.
12 mg arm: 70.3 lb average reduction at 80 weeks
9 mg arm: 64.4 lb average reduction at 80 weeks
4 mg arm: 47.2 lb average reduction at 80 weeks
45.3% of 12 mg participants achieved at least 30% body-weight reduction
Why the third receptor matters
Direct answer
Retatrutide is a triple agonist. Mounjaro acts on GLP-1 and GIP; Ozempic acts on GLP-1.
Mounjaro hits two receptors. Ozempic hits one. Retatrutide hits three - GLP-1, GIP, and glucagon.
That is the clinical reason the result is being treated differently. The result is not just a branding story. It comes from a different receptor profile, which is why safety, tolerability, and approval status matter alongside the headline number.
What this does not mean in Australia
Direct answer
The result doesn't make retatrutide approved in Australia and doesn't replace clinical advice.
It does not mean retatrutide is approved in Australia. It does not mean a doctor can prescribe a finished retatrutide medicine today. It does not mean a lab vial is a replacement for clinical care.
It means the trial result arrived before the Australian medicine market. That gap is why the batch, COA, HPLC, payment method, dispatch, and support matter for readers looking at research-grade pages.
What to check if you are researching the peptide now
Direct answer
Ignore the hype first. Check the product record.
A research-grade seller should show the vial strength, batch ID, COA, HPLC purity, payment method, dispatch origin, and support before payment.
If those details are hidden, the page is asking you to trust the label instead of the batch record.
Strength shown clearly
Batch ID visible before checkout
COA and HPLC tied to the batch
Protected payment and Australian dispatch shown before payment
Research peptides are not approved by the TGA for human use. Supplier links are for checking visible batch and payment details, not medical advice.
How we reviewed this article
This article was checked against primary source material, regulator pages, and the exact seller claims named on this site. The goal is to keep triumph-1: the 28.3% retatrutide result useful without turning it into medical advice or a fake clinical recommendation.
Checked points
TRIUMPH-1 topline numbers
Australian approval status
No dosing or medical advice